EA201691265A1 - Соединения агонисты gpr142 - Google Patents

Соединения агонисты gpr142

Info

Publication number
EA201691265A1
EA201691265A1 EA201691265A EA201691265A EA201691265A1 EA 201691265 A1 EA201691265 A1 EA 201691265A1 EA 201691265 A EA201691265 A EA 201691265A EA 201691265 A EA201691265 A EA 201691265A EA 201691265 A1 EA201691265 A1 EA 201691265A1
Authority
EA
Eurasian Patent Office
Prior art keywords
gpr142
agonists
connections
group
chronoch
Prior art date
Application number
EA201691265A
Other languages
English (en)
Inventor
Тяньвэй Ма
Ми Эмили Цзэн
Чжи Лун Ху
Лянь Чжу Лю
Цзинье Чжоу
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201691265A1 publication Critical patent/EA201691265A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Abstract

Настоящее изобретение относится к соединениям формулыгде R выбран из группы, состоящей из СН, СН(СН), CHCN, CHCHF, CHCF,СНСНОСНи СНС(О)ОСН(СН)Rвыбран из группы, состоящей из CF, OCFи Cl; Rвыбран из группы, состоящей из Н и F; или их фармацевтически приемлемой соли.
EA201691265A 2014-02-14 2015-01-22 Соединения агонисты gpr142 EA201691265A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2014/072083 WO2015120610A1 (en) 2014-02-14 2014-02-14 Gpr142 agonist compound
PCT/CN2015/071286 WO2015120768A1 (en) 2014-02-14 2015-01-22 Gpr142 agonist compounds

Publications (1)

Publication Number Publication Date
EA201691265A1 true EA201691265A1 (ru) 2016-11-30

Family

ID=53799520

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691265A EA201691265A1 (ru) 2014-02-14 2015-01-22 Соединения агонисты gpr142

Country Status (10)

Country Link
US (1) US9861613B2 (ru)
EP (1) EP3105207B1 (ru)
JP (1) JP6298172B2 (ru)
CN (1) CN106170478B (ru)
AU (1) AU2015218135B2 (ru)
CA (1) CA2935109A1 (ru)
EA (1) EA201691265A1 (ru)
ES (1) ES2693545T3 (ru)
MX (1) MX2016010411A (ru)
WO (2) WO2015120610A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138631A1 (en) 2015-03-03 2016-09-09 Eli Lilly And Company Imidazo benzamide compounds
WO2018014337A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide
EP3817811B1 (en) 2018-07-04 2024-04-03 Boehringer Ingelheim International GmbH Triazole benzamide derivatives as gpr142 agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
US20070032475A1 (en) * 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20090270394A1 (en) * 2008-04-28 2009-10-29 Galemmo Jr Robert Cyclylamine derivatives as calcium channel blockers
US8188098B2 (en) * 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
EP2404896A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Cyclohexane derivative having npy y5 receptor antagonism
AR079170A1 (es) * 2009-12-10 2011-12-28 Lilly Co Eli Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par

Also Published As

Publication number Publication date
CN106170478B (zh) 2019-04-09
EP3105207A4 (en) 2017-06-21
CA2935109A1 (en) 2015-08-20
AU2015218135B2 (en) 2017-06-08
EP3105207A1 (en) 2016-12-21
ES2693545T3 (es) 2018-12-12
JP2017505797A (ja) 2017-02-23
WO2015120610A1 (en) 2015-08-20
WO2015120768A1 (en) 2015-08-20
MX2016010411A (es) 2016-10-17
JP6298172B2 (ja) 2018-03-20
AU2015218135A1 (en) 2016-07-14
US9861613B2 (en) 2018-01-09
EP3105207B1 (en) 2018-08-22
CN106170478A (zh) 2016-11-30
US20170165234A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CY1120705T1 (el) Καινοφανεις αναστολεις αποακετυλασων ιστονων
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201691799A1 (ru) Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201692193A1 (ru) Способы получения ингибитора jak1 и его новых форм
EA201691302A1 (ru) Новые гетероциклические соединения
EA201890522A1 (ru) Способ получения противогрибковых соединений
EA201792021A1 (ru) Ингибитор jak
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201791684A1 (ru) Селективные ингибиторы bace1
EA201790112A1 (ru) Гетероциклические соединения и их применение в качестве ингибиторов орфанного рецептора гамма-t, родственного рецепторам ретиноидов (ror)
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201691071A1 (ru) Фенилтриазолопиридиновые соединения
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
EA201690879A1 (ru) Новое триазолопиридиновое соединение
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201691618A1 (ru) Способ получения сульфамидных производных пиримидина